News Release: July 30, 2025
Lurasidone Intermediate Price, Production, Latest News and Developments in 2025
Lurasidone Intermediate price trend and production News
Lurasidone Intermediate Price Trend in Past Five Years and Factors Impacting Price Movements
Over the past five years, the Lurasidone Intermediate price has experienced significant fluctuations due to a combination of factors including raw material costs, supply chain challenges, regulatory changes, and shifting global demand. In 2020, the average price of Lurasidone Intermediate was around $4,300/MT. During this year, the market remained relatively stable due to moderate demand from pharmaceutical manufacturers. However, in 2021, prices saw a notable increase, climbing to approximately $4,800/MT, driven by rising costs of raw materials and increased logistical expenses post-COVID-19.
The year 2022 brought even more significant changes. Lurasidone Intermediate price surged to $5,500/MT in Q2, peaking at around $5,800/MT by the year-end. This sharp rise was largely due to geopolitical tensions affecting the global supply of key chemical feedstocks and a temporary shutdown of several manufacturing facilities in Asia. The supply constraints led to a tightening of inventories and resulted in upward pressure on prices.
In 2023, prices saw a mild correction, averaging around $5,200/MT throughout the year. Increased production capacity in India and China contributed to a more balanced market, while demand from global pharmaceutical companies remained steady. However, the price stability was challenged again by currency fluctuations and inflation in logistics costs.
By early 2024, Lurasidone Intermediate prices began to stabilize further, with the average hovering around $5,000/MT. A global push for sustainable pharmaceutical manufacturing and increased adoption of green chemistry has influenced both production costs and strategic investments in cleaner technologies. This transition has had a moderate effect on Lurasidone Intermediate production costs, and hence the pricing.
As of 2025, the Lurasidone Intermediate price news indicates a more consolidated and efficient supply chain, resulting in a slight downward adjustment in prices. Currently, the Lurasidone Intermediate price is estimated at around $4,700/MT in Q1 of 2025. Factors such as the expansion of production facilities in Eastern Europe and Southeast Asia, reduced dependence on single-source suppliers, and an overall improvement in freight services are contributing to a more competitive pricing landscape.
Additionally, the steady increase in Lurasidone Intermediate sales volume across developed and emerging markets has helped manufacturers achieve economies of scale, marginally lowering the cost per metric ton. The demand for antipsychotic drugs, especially in North America and parts of Europe, continues to drive the Lurasidone Intermediate production network, aligning capacity expansion with regional needs.
Looking ahead, the Lurasidone Intermediate price trend is expected to remain relatively stable in 2025, with slight quarter-on-quarter movements driven by seasonal variations in demand and raw material availability. The market is also benefiting from technological innovations that are enabling faster and more cost-effective production cycles.
Lurasidone Intermediate Price Trend Quarterly Update in $/MT
- Q1 2025: $4,700/MT
- Q2 2025: $4,850/MT (slight rise due to seasonal procurement from North America)
- Q3 2025: $4,780/MT (moderate dip post bulk purchase cycle)
- Q4 2025: $4,900/MT (end-of-year contract renewals driving slight spike)
Global Lurasidone Intermediate Import-Export Business Overview
The global import-export landscape for Lurasidone Intermediate in 2025 reflects the broader trends in the pharmaceutical raw material supply chain. The segment has become more geographically diversified, with multiple production hubs supporting robust global trade. Countries such as India, China, the United States, Germany, and Japan are key players in this domain.
India and China continue to dominate the export of Lurasidone Intermediate, accounting for nearly 65% of the global exports combined. Both countries have established cost-efficient manufacturing ecosystems and benefit from extensive experience in active pharmaceutical ingredient (API) supply chains. Indian manufacturers have especially gained prominence for producing high-purity grades of Lurasidone Intermediate compliant with stringent USFDA and EMA guidelines.
In 2025, India’s Lurasidone Intermediate production capacity is expected to grow by over 8% compared to the previous year, led by capacity expansions in Gujarat and Telangana. Exports from India are targeted primarily toward North America, Europe, and Southeast Asia. The Lurasidone Intermediate sales volume from India has seen a 12% increase year-on-year, supported by consistent demand from generic drug makers.
China, although experiencing tighter environmental regulations, remains a major player due to its large-scale production units. However, the country has shifted towards focusing on higher-margin intermediates and specialty APIs, slightly reducing its Lurasidone Intermediate export volume. Nonetheless, its presence in the global trade remains critical, particularly for Asian and Middle Eastern markets.
On the import side, the United States remains the largest importer of Lurasidone Intermediate, driven by high domestic demand for Lurasidone-based antipsychotic medications. In 2025, the US has increased its imports by nearly 9% compared to the previous year, largely to maintain consistent inventories and mitigate risks associated with global supply disruptions.
European nations, particularly Germany and France, also maintain steady import levels. The Lurasidone Intermediate price news in Europe suggests that EU buyers are now entering into long-term contracts to secure pricing predictability amid fluctuating global logistics rates. European importers have also started sourcing from Eastern Europe, where new manufacturing facilities in Poland and Hungary are emerging as alternative suppliers.
In Asia, countries like Japan and South Korea are both significant importers and consumers of Lurasidone Intermediate. Their domestic pharmaceutical industries are focused on innovation and require high-grade intermediates. The Lurasidone Intermediate production in South Korea is growing, but domestic demand still outweighs supply, necessitating imports.
Meanwhile, Southeast Asian nations such as Vietnam, Thailand, and Malaysia are increasingly importing Lurasidone Intermediate for their growing generics manufacturing sectors. This regional shift in demand is creating new trade routes and diversifying the global Lurasidone Intermediate sales volume.
In Latin America, Brazil and Argentina are notable importers. Their pharmaceutical markets have shown growing interest in expanding psychotropic drug portfolios, which include Lurasidone-based therapies. The import volume to Latin America has increased marginally, although logistical constraints continue to pose a challenge.
Africa remains a minor player in the Lurasidone Intermediate import-export ecosystem, with limited pharmaceutical manufacturing capacity. However, nations like South Africa and Egypt are gradually increasing imports for formulation purposes.
Key global trends in the Lurasidone Intermediate price news highlight a move toward supply chain resilience. Companies are reducing overdependence on single-country sources, and several multinational pharmaceutical firms have diversified their sourcing strategies in 2025.
In terms of pricing, international contracts are now being structured with flexible pricing clauses to accommodate quarterly price adjustments. This reflects the estimated Lurasidone Intermediate price trend observed across various trade partners. Currency fluctuations, especially the US dollar and Chinese yuan dynamics, are influencing price negotiations.
Another major development in 2025 has been the digitization of the procurement process. Many importers are adopting online sourcing platforms for real-time Lurasidone Intermediate price discovery and contract management, which is reducing the negotiation cycle and improving operational transparency.
In conclusion, the global Lurasidone Intermediate trade environment in 2025 is characterized by increased diversification, gradual pricing normalization, and growing adoption of smart supply chain practices. The market is expected to remain robust with moderate to high growth in Lurasidone Intermediate sales volume across emerging and developed regions.
Request a sample or explore more insights here: https://datavagyanik.com/reports/lurasidone-intermediate-market/
Lurasidone Intermediate Production Trends by Geography
Lurasidone Intermediate production has witnessed significant growth over the years, with key pharmaceutical manufacturing hubs ramping up their capacities in response to increasing global demand for antipsychotic medications. In 2025, the production trends reflect a balanced interplay between cost-efficiency, regulatory compliance, and geographical accessibility. Major regions contributing to the Lurasidone Intermediate production landscape include Asia-Pacific, North America, and Europe, with emerging contributions from Latin America and Eastern Europe.
Asia-Pacific remains the largest producer of Lurasidone Intermediate globally. Within this region, India and China are the primary contributors. India’s pharmaceutical sector continues to benefit from a well-established network of intermediate and API manufacturers, especially in states like Gujarat, Maharashtra, and Telangana. In 2025, production volumes in India have grown by approximately 8–10% due to recent capacity expansions and government incentives aimed at strengthening domestic production. Indian manufacturers are focusing on upgrading their facilities to meet global regulatory standards, such as those of the USFDA and EMA, making the country a preferred outsourcing hub for major international pharmaceutical companies.
China, on the other hand, has maintained a strong production base, although it has slightly reduced its output of Lurasidone Intermediate in 2025 to concentrate on higher-value pharmaceutical products. Nevertheless, Chinese producers still command a significant share of global production, thanks to large-scale plants and advanced process technologies. The industry in China is experiencing consolidation, with a focus on environmental sustainability and higher purity levels, which has influenced both production methods and output volumes.
North America, particularly the United States, has increased its local production capacities, though it still relies partially on imports to meet domestic demand. Several American pharmaceutical companies have initiated backward integration projects to secure a stable supply of Lurasidone Intermediate. These investments are also part of a broader strategy to reduce supply chain vulnerabilities exposed during the COVID-19 pandemic. The US is seeing the emergence of modular production units, supported by strong R&D capabilities, which allow flexible and scalable manufacturing.
Europe follows closely, with Germany, Switzerland, and France being key contributors to Lurasidone Intermediate production. In 2025, European producers are emphasizing eco-friendly manufacturing and high-quality compliance, aligning with the EU’s stricter environmental and pharmaceutical regulations. These countries often supply to regulated markets and therefore focus on smaller, high-purity batches, suitable for patented and specialty formulations. The region is also investing in digital process automation and green chemistry principles to maintain competitiveness.
Eastern Europe, particularly Poland, Hungary, and the Czech Republic, is an emerging production zone. The relatively low cost of manufacturing and access to the EU market make these locations attractive for contract manufacturers. Several multinational firms are establishing partnerships or subsidiaries in these countries to diversify their production networks and reduce overreliance on Asia-Pacific sources.
Latin America has started to play a minor but growing role in Lurasidone Intermediate production. Brazil is leading the region, with support from its strong domestic pharmaceutical industry. Local production is primarily aimed at meeting internal demand and reducing dependence on imports, with expansion efforts supported by government initiatives encouraging pharmaceutical self-reliance.
In Africa, production remains minimal due to limited infrastructure and technical expertise. However, countries such as South Africa are exploring pharmaceutical manufacturing as a strategic industry for future development.
Overall, the global production of Lurasidone Intermediate in 2025 is characterized by a shift toward decentralized and diversified manufacturing networks. While Asia continues to dominate, other regions are increasingly investing in capacity building to ensure supply chain resilience, quality control, and strategic independence.
Lurasidone Intermediate Market Segmentation
Segments:
- By Application
- By End-Use Industry
- By Purity Level
- By Region
- By Production Technology
Market Segmentation Explanation
1. By Application
Lurasidone Intermediate is primarily used in the synthesis of Lurasidone Hydrochloride, an antipsychotic medication commonly prescribed for the treatment of schizophrenia and bipolar depression. As such, the pharmaceutical formulation segment dominates the application-based market segmentation. The increasing incidence of mental health disorders globally has led to a sustained demand for Lurasidone Intermediate, with generic and branded formulations relying on consistent intermediate supply. In 2025, this segment continues to expand due to the growing awareness of psychiatric illnesses and the introduction of more accessible treatment options in developing nations.
2. By End-Use Industry
The main end-use industry is the pharmaceutical sector, which comprises both generic drug manufacturers and research-based companies. Generic manufacturers form the bulk of the market, particularly in regions like India, Southeast Asia, and Latin America, where cost-effective treatment options are in high demand. Meanwhile, innovator pharmaceutical companies, especially in the US and Europe, represent the premium segment, demanding high-purity Lurasidone Intermediate for patented drug formulations. This segmentation also includes contract development and manufacturing organizations (CDMOs), which are becoming important stakeholders in supplying intermediates globally.
3. By Purity Level
Lurasidone Intermediate is available in various purity grades depending on the final application. The two major sub-segments are standard purity (typically 95–98%) and high purity (above 98.5%). The high-purity segment commands a premium and is essential for formulations intended for regulated markets like the US, EU, and Japan. In contrast, standard purity intermediates are widely used in domestic formulations in less regulated markets. In 2025, the high-purity segment is witnessing faster growth due to stricter global regulatory compliance and quality assurance demands from pharmaceutical companies.
4. By Region
From a regional perspective, the Asia-Pacific region leads in both production and consumption. Within this, India is the fastest-growing country in terms of market size, while China continues to hold a significant share despite a slight production taper. North America, particularly the US, remains the largest consumer, driven by a high patient base and advanced healthcare infrastructure. Europe follows closely, focusing on sustainable and high-quality production. Latin America and the Middle East are emerging markets with rising healthcare investments, which are expected to increase their consumption share over the next few years.
5. By Production Technology
This segment includes traditional batch processing and newer continuous manufacturing technologies. While batch production remains the most prevalent method globally due to its scalability and flexibility, continuous production is gaining traction in developed regions due to its advantages in yield optimization and waste reduction. In 2025, several companies in North America and Europe have shifted to continuous flow synthesis for Lurasidone Intermediate, especially for high-purity output. This trend is expected to reshape the global competitive landscape by offering better cost efficiency and environmental compliance.
Leading Segment Insights
Among all segments, the pharmaceutical application and high-purity product categories are leading in terms of value contribution. The increasing demand for regulated market approvals and premium drug quality is driving the need for highly purified intermediates. Additionally, regional production diversification and the use of advanced synthesis technologies are reshaping supply and demand dynamics.
The end-use pharmaceutical segment also continues to expand due to a global focus on mental health treatments. As more health systems worldwide include mental illness in public health agendas, the demand for Lurasidone-based medications—and by extension, Lurasidone Intermediate—is projected to grow steadily.